Top Tweets for #Immunoonc

1 day ago

In an interview at #IMS26, Catherine Lecat of @ucl discussed the safety of bispecific antibody re-step-up dosing after prolonged treatment delays. Click here to learn more: 🎥 ➡️ https://t.co/FqTe6lMlTa #MultipleMyeloma #Myeloma #MMsm #ImmunoOnc #HemOnc

1

3

0

387

2 days ago

Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma [Jan 30, 2023] @Eddie_Cliff et al. @JCO_ASCO https://t.co/3I1RX9JmDv #mmsm #ImmunoOnc #IDonc

mtmdphd's tweet photo. Acknowledging Infection Risk in Bispecific Antibody Trials in the Treatment of Multiple Myeloma [Jan 30, 2023] @Eddie_Cliff et al. @JCO_ASCO https://t.co/3I1RX9JmDv #mmsm #ImmunoOnc #IDonc https://t.co/w1ARFdGm2V

1

5

1

383

2 days ago

Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma [Jul 17, 2025] Kasomva et al. @BloodPortfolio https://t.co/lTMclN4Jcn #mmsm #ImmunoOnc #IDonc #LymphoidNeoplasia

mtmdphd's tweet photo. Molecular and Immunological Determinants of Long-Term Survival in Multiple Myeloma [Jul 17, 2025] Kasomva et al. @BloodPortfolio
https://t.co/lTMclN4Jcn #mmsm #ImmunoOnc #IDonc #LymphoidNeoplasia https://t.co/smF0TPwNXG

0

1

0

137

2 days ago

IVIG Replacement Therapy and Clinical Outcomes in Adults With Hematologic Malignancies and Secondary Hypogammaglobulinemia: A Propensity Score-Matched Analysis [Sep 2026] Khan et al. #SOHO2026 Abst MM-856 https://t.co/vA2gYGNbIy #mmsm #ImmunoOnc #IDonc

mtmdphd's tweet photo. IVIG Replacement Therapy and Clinical Outcomes in Adults With Hematologic Malignancies and Secondary Hypogammaglobulinemia: A Propensity Score-Matched Analysis [Sep 2026] Khan et al. #SOHO2026 Abst MM-856 https://t.co/vA2gYGNbIy #mmsm #ImmunoOnc #IDonc https://t.co/DEVJtArTZW

0

4

1

0

251

2 days ago

National trends in pneumonia-related admissions among patients with multiple myeloma [Sep 9, 2026] Brunner et al. #SOHO2026 Abstract MM-826 https://t.co/ezPd699kLR #mmsm #ImmunoOnc #IDonc #hpeonc

mtmdphd's tweet photo. National trends in pneumonia-related admissions among patients with multiple myeloma [Sep 9, 2026] Brunner et al. #SOHO2026 Abstract MM-826 https://t.co/ezPd699kLR #mmsm #ImmunoOnc #IDonc #hpeonc https://t.co/dpuxgGamFL

0

1

0

187

2 days ago

Watch our recent interview with @AndreaNecchi from #ESMO26 to hear final pathological and radiological outcomes, and initial EFS from the GDFather-NEO trial of nivolumab ± visugromab in #MIBC 📈🔬 🎥: https://t.co/3dnQL6VWX3 #Oncology @myESMO #TrialUpdate #ImmunoOnc #BladderCancer #BCSM

0

5

3

0

532

2 days ago

Association of immunotherapy and immunosuppression with severe COVID-19 disease in patients with cancer [Sep 13, 2022] @ZiadBakouny et al. @TMWiseDraper S772–S773 502P @Annals_Oncology https://t.co/1XtiMgjWQO @COVID19nCCC #COVID19nCancer #ImmunoOnc #IDonc

0

174

4 days ago

Where do BCMA-targeted bispecific antibodies currently stand in AL #amyloidosis?🩸 We asked Giada Bianchi (@TheBianchiLab) of @BrighamWomens at #SOHO2026 - watch the interview to hear her insights: ➡️ https://t.co/1b9f0GSVPR #ImmunoOnc #HemOnc

1

6

1

726

5 days ago

#ESMO26 | @PAscierto discusses clinical updates in #cellulartherapies for solid tumors, barriers to adoption in Europe, and first-in-human results of the live biotherapeutic MB097 with pembrolizumab in #melanoma 💉📈 @myESMO #MelSM #CART #ImmunoOnc

VJOncology's tweet photo. #ESMO26 | @PAscierto discusses clinical updates in #cellulartherapies for solid tumors, barriers to adoption in Europe, and first-in-human results of the live biotherapeutic MB097 with pembrolizumab in #melanoma 💉📈

@myESMO #MelSM #CART #ImmunoOnc https://t.co/0r8LiZdRC9

0

2

0

234

5 days ago

At #ESMO26, Joana Ribeiro discusses first results of UNLOCK 14 of short-term preoperative durvalumab in stage I #TNBC, options after neoadjuvant therapy, and the OPT-PEMBRO de-escalation trial @myESMO #BCSM #BreastCancer #ImmunoOnc @GustaveRoussy

VJOncology's tweet photo. At #ESMO26, Joana Ribeiro discusses first results of UNLOCK 14 of short-term preoperative durvalumab in stage I #TNBC, options after neoadjuvant therapy, and the OPT-PEMBRO de-escalation trial

@myESMO #BCSM #BreastCancer #ImmunoOnc @GustaveRoussy https://t.co/B7A8H45wGJ

0

3

1

0

892

6 days ago

At #ESMO26, Luigi Lorini discusses results of the phase 2 TEPMEETCET study of EGFR and c-MET inhibition in platinum- and IO-resistant recurrent/metastatic #HeadandNeckCancer, and whether it could move earlier @myESMO #HNCSM #ImmunoOnc #TrialUpdate @HumanitasMilano

VJOncology's tweet photo. At #ESMO26, Luigi Lorini discusses results of the phase 2 TEPMEETCET study of EGFR and c-MET inhibition in platinum- and IO-resistant recurrent/metastatic #HeadandNeckCancer, and whether it could move earlier

@myESMO #HNCSM #ImmunoOnc #TrialUpdate @HumanitasMilano https://t.co/rZseqDA7vM

0

149

6 days ago

🎥 New interview from #ESMO26! We spoke with @JL_Reading about his latest research on how the T cell network is remodelled during early #LungCancer development 🫁 @myESMO #LCSM #ImmunoOnc

VJOncology's tweet photo. 🎥 New interview from #ESMO26!

We spoke with @JL_Reading about his latest research on how the T cell network is remodelled during early #LungCancer development 🫁

@myESMO #LCSM #ImmunoOnc https://t.co/n4IlJNrtNy

1

5

1

0

346

7 days ago

At #ASCO26, @JosephMCurryMD explores recent advancements in #HeadandNeckCancer and cutaneous cancers to optimize #surgery and #immunotherapy 💉📈 Watch: https://t.co/6Xm6deICXx #Oncology #SurgOnc #ImmunoOnc @ASCO #hncSM #SkcSM

0

125

7 days ago

#iwHRMM26 | @AjayNookaMD is up next! He is currently on stage giving his talk titled: 'Immunotherapeutic sequencing for newly diagnosed primary refractory high-risk myeloma'. #MultipleMyeloma #MMsm #ImmunoOnc

$VJHemOnc's tweet photo. #iwHRMM26 | @AjayNookaMD is up next! He is currently on stage giving his talk titled: 'Immunotherapeutic sequencing for newly diagnosed primary refractory high-risk myeloma'. #MultipleMyeloma #MMsm #ImmunoOnc https://t.co/NkZ7LRiC4p$

1

6

3

0

598

7 days ago

Session 9 of #iwHRMM26 is underway! @ShoMidha is starting it off by discussing early T-cell engaging therapy vs ASCT in high-risk NDMM and PCL. #MultipleMyeloma #MMsm #LYMsm #ImmunoOnc

VJHemOnc's tweet photo. Session 9 of #iwHRMM26 is underway!

@ShoMidha is starting it off by discussing early T-cell engaging therapy vs ASCT in high-risk NDMM and PCL.

#MultipleMyeloma #MMsm #LYMsm #ImmunoOnc https://t.co/WU65w4EB9u

1

5

1

0

547

7 days ago

#iwHRMM26 | @bhemato of @MedicalCollege is on stage right now discussing the timing of immunotherapy in randomized trials for high-risk #myeloma. #MMsm #MultipleMyeloma #ImmunoOnc #CTSM

VJHemOnc's tweet photo. #iwHRMM26 | @bhemato of @MedicalCollege is on stage right now discussing the timing of immunotherapy in randomized trials for high-risk #myeloma.

#MMsm #MultipleMyeloma #ImmunoOnc #CTSM https://t.co/UyJZoBqLxS

0

4

3

0

543

7 days ago

@RaabMarc of @HDMyeloma is kicking off day 2 of #iwHRMM26 with his talk on 'T-cell engager combinations to overcome HR #MultipleMyeloma'. #MMsm #ImmunoOnc #Myeloma

VJHemOnc's tweet photo. @RaabMarc of @HDMyeloma is kicking off day 2 of #iwHRMM26 with his talk on 'T-cell engager combinations to overcome HR #MultipleMyeloma'.

#MMsm #ImmunoOnc #Myeloma https://t.co/rKVD2136f2

0

7

4

0

396

7 days ago

#iwHRMM26 | Doris Hansen of @MoffittNews is up next with her talk on BMS 986453 (tunlucabtagene autoleucel), a dual-targeting BCMA x GPRC5D CAR-T for the treatment of R/R #MultipleMyeloma. #CART #MMsm #ImmunoOnc

VJHemOnc's tweet photo. #iwHRMM26 | Doris Hansen of @MoffittNews is up next with her talk on BMS 986453 (tunlucabtagene autoleucel), a dual-targeting BCMA x GPRC5D CAR-T for the treatment of R/R #MultipleMyeloma.

#CART #MMsm #ImmunoOnc https://t.co/CkEtAYQDNI

2

4

0

638